Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532347 | 1.00 | PARP1 (0.57) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL5342897 | 1.00 | PARP1 (0.57) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL532882 | 0.88 | PARP1 (0.57) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL13863089 | 0.84 | PARP1 (0.53) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL6998657 | 0.82 | PARP1 (0.59) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL531620 | 0.81 | ALDH1A1 (0.38) | PARP1PDE3BPDE3AUSP2GAA | |
| SCHEMBL532921 | 0.81 | USP2 (0.48) | PARP1USP2GAAHSD17B10 | |
| SCHEMBL531954 | 0.80 | ALOX5 (0.55) | PARP1PDE3BPDE3ASMYD3GAA | |
| SCHEMBL6999639 | 0.80 | PARP1 (0.49) | PARP1PDE3BPDE3ASMYD3ALDH1A1 | |
| SCHEMBL7711338 | 0.80 | PARP1 (0.52) | PARP1PDE3BPDE3ASMYD3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282610-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THE USE THEREOF IN MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-6914059-B2 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AG (DE) | 2005-07-05 | — | — | US | disclosed |
| US-20040006075-A1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AG (DE) | 2004-01-08 | — | — | US | disclosed |
| EP-1282610-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THE USE THEREOF IN MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001081323-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THE USE THEREOF IN MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006075-A1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | CYP4Z1, XDH, CYP3A5 | PARP1 2525/4885PDE3B 4256/4885PDE3A 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.